From 17th-22nd April, Mat and Vicky headed to Munich, Germany for ESCMID GLOBAL 2026.
ESCMID Global is one of the world’s biggest conferences on microbiology and infectious disease, so was a great opportunity to share new data and connect with a global research community.
Poster presentations and new connections
It was a busy but productive week. One highlight was our poster presentation sharing our latest data on the IV efficacy of NI01 in a bloodstream infection model. Despite an overwhelming conference size of 18000 attendees, we managed to make some valuable new connections. We also caught up with some old friends and colleagues from across the globe who had made the journey to Munich.
AMR policy forum
AMR was a central theme of the conference, with a dedicated AMR science-policy forum held on 17th April. Speakers from the Global Leaders Group on Antimicrobial Resistance, CARB-X, LifeArc, the Novo Nordisk Foundation, and the Gates Foundation discussed the relationship between science and policy in the AMR space. They also updated attendees on the progress towards the creation of the Independent Panel for Evidence for Action against AMR. A thought provoking day and a good start to the week.
Green Travel Award
Despite Plymouth and Munich being situated ~1800km apart, Vicky was able to make the entire journey using public transport. This earned her an ESCMID green travel award as one of the top ten attendees travelling the furthest without flying. As well as earning the right to be extremely smug for the whole conference, the shiny badge was a really good conversation starter. Hopefully this inspired a few other attendees to consider taking the train to Stockholm next year for ESCMID Global 2027!
What's next?
With the summer now feeling like it’s well underway, our attention is turning to September and GAMRIC, the 2nd Global AMR Innovators Conference in Lisbon, Portugal. This will be Amprologix’s first time at GAMRIC, but following on from the success of ESCMID we are looking forward to engaging with a more focused community. In particular we will discuss our ongoing work on our AI-driven drug discovery platform, and how this is shaping our antimicrobial peptide development pipeline.
